What is Viatris Inc. (VTRS) DCF Fair Value and Intrinsic Value in 2026?

Viatris Inc. (VTRS) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is Viatris Inc.'s historical Return on Invested Capital (ROIC) and Moat Rating?

Viatris Inc. operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic) with an economic moat rating of NONE. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is Viatris Inc.'s financial health rating and Piotroski F-Score?

Viatris Inc.'s balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor Viatris Inc. (VTRS) for quarterly SEC filing thesis breaks?

LocalAlpha audits Viatris Inc.'s 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksVTRS

VTRS

Viatris Inc.Healthcare / Drug Manufacturers - Specialty & GenericINTACT

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Share Price

$16.57

52W: $9.43 - $18.39

DCF Fair Value

$35.67

+53.5% MoS

Thesis Hub

P/E (TTM)

20x

ROIC

9.5%

Operating Margin

12.6%

FCF Yield

14.1%

Debt / Equity

0.96x

Piotroski Score

7/9

Altman Z-Score

3.01

Market Cap

$19B

Price vs. Intrinsic Value Corridor

Margin of Safety Buy Zone (<25% Discount)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$35.67

MOS Buy Target (-25%)

$26.75

Valuation Overlays: DCF Fair Value ($35.67) 25% MOS Buy Target ($26.75)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$16.57

DCF Fair Value

$35.60

+53.5% MoS

Starting Free Cash Flow ($M)$2,677M

$100M$2,677M (Reported)$50,000M

Stage 1 Growth (Years 1-5)6.3%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$12,100M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$22.8B

PV of Terminal Value

$30.2B

Implied Enterprise Value

$53.0B

Implied Equity Value

$40.9B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$2,846	$3,025	$3,216	$3,418	$3,633	$3,797	$3,968	$4,146	$4,333	$4,528
Present Value (PV)	$2,611	$2,546	$2,483	$2,421	$2,361	$2,264	$2,171	$2,081	$1,995	$1,913

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number

N/A

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

Not calculable here: the formula takes a square root of EPS × book value, so it breaks down when trailing earnings (or book value) are negative. A company losing money has no defensive-investor price under Graham's classic test — lean on the DCF and solvency scores instead.

EPS: $-0.37BVPS: $12.59

Revised Graham Formula

N/A

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings13.3% Yield

$2.21 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $2.5BYield: 13.3%

Reverse DCF: Market Growth Expectation

EXTREMELY LOW BARRIER

-8.4% CAGR (Next 10 Yrs)

At the current price of $16.57, the market is assuming the business will compound Free Cash Flow at -8.4% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

✓ Low market hurdle: Easy for a wide-moat compounder to beat.

Autonomous Thesis Underwriting

Surveil VTRS with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Viatris Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 12.6% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track VTRS & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: Viatris Inc. (VTRS) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Viatris Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Viatris Inc. has an estimated DCF intrinsic fair value of $35.67 per share compared to its current market price of $16.57. This represents an estimated 53.5% margin of safety (trading below fair value). Additionally, its classic Benjamin Graham Number stands at $N/A.